About Ongeno
Ongeno is a company based in Krakow (Poland) founded in 2020. Ongeno has raised $3.62 million across 1 funding round. Ongeno operates in a competitive market with competitors including QurAlis, Kiadis Pharma, Priothera, Jasper Therapeutics and Rubius Therapeutics, among others.
- Headquarter Krakow, Poland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Ongeno Sp. Z O.O
-
Annual Revenue
$143.09 K (USD)35as on Dec 31, 2019
-
Net Profit
$3.36 K (USD)-47as on Dec 31, 2019
-
EBITDA
$5.04 K (USD)-38as on Dec 31, 2019
-
Total Equity Funding
$3.62 M (USD)
in 1 rounds
-
Latest Funding Round
$3.62 M (USD), Series A
Jan 21, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ongeno
Ongeno has successfully raised a total of $3.62M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.62 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Ongeno
Investment portfolio details for Ongeno
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ongeno
Detailed financials for Ongeno
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ongeno Comparisons
Peer comparison for Ongeno
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ongeno
Ongeno operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QurAlis, Kiadis Pharma, Priothera, Jasper Therapeutics and Rubius Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs and CSF devices are developed for ALS treatment.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for hematological malignancies are developed by Priothera.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
|
| Locked | Locked | Locked |
Genetically modifying hematopoietic stem cells to create RBC therapeutics in metabolic deficiencies, autoimmune disorders, and cancer
|
|
| Locked | Locked | Locked |
Remyelinating therapies for multiple sclerosis are developed.
|
Detailed competitors of Ongeno
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ongeno
Complete news archive for Ongeno
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ongeno
Ongeno was founded in 2020 and raised its 1st funding round 5 years after it was founded.
Ongeno is headquartered in Krakow, Poland. It is registered at Krakow, Lesser Poland Voivodeship, Poland.
Ongeno is a funded company, having raised a total of $3.62M across 1 funding round to date.
Annual revenue of Ongeno is $143.09K as on Dec 31, 2019.
Ongeno was founded in 2020 in Krakow, Poland, within the biotechnology sector. Autologous bone marrow stem cell transplant therapy is being developed by the company specifically for multiple sclerosis. Operations focus on advancing this treatment through research and clinical processes. The therapy targets disease progression in patients, with activities centered in Poland.
Ongeno's top competitors include QurAlis, Jasper Therapeutics and Priothera.